• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965; PubMed=24735930).
  

PubMed=22194965; DOI=10.1371/journal.pone.0028973; PMCID=PMC3237573
Atefi M., von Euw E.M., Attar N., Ng C., Chu C., Guo D.-L., Nazarian R., Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S., Ribas A.
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
PLoS ONE 6:E28973-E28973(2011)

PubMed=24735930; DOI=10.1186/1476-4598-13-83; PMCID=PMC4021505
Lassen A., Atefi M., Robert L., Wong D.J.L., Cerniglia M., Comin-Anduix B., Ribas A.
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Mol. Cancer 13:83.1-83.14(2014)

PubMed=29229836; DOI=10.1073/pnas.1712064115; PMCID=PMC5748184
Su Y.-P., Wei W., Robert L., Xue M., Tsoi J., Garcia-Diaz A., Homet Moreno B., Kim J., Ng R.H.-Y., Lee J.W., Koya R.C., Comin-Anduix B., Graeber T.G., Ribas A., Heath J.R.
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.
Proc. Natl. Acad. Sci. U.S.A. 114:13679-13684(2017)